Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CEFTIBUTEN vs CEMIPLIMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

CEFTIBUTEN vs CEMIPLIMAB: Safety Overview

Metric CEFTIBUTEN CEMIPLIMAB
Total FAERS Reports 150 1,020
Deaths Reported 1 175
Death Rate 0.7% 17.2%
Hospitalizations 26 651
Average Patient Age 37.1 yrs 68.9 yrs
% Female Patients 58.9% 36.6%
FDA Approval Date Dec 20, 1995 N/A
Manufacturer N/A Regeneron Pharmaceuticals, Inc.
Route N/A INTRAVENOUS
Marketing Status Discontinued N/A